0
1
1
0
1
1
The Modified Rankin Scale (mRS) is the most widely used outcome measure for assessing the degree of disability or dependence in the daily activities of patients who have suffered a stroke or other neurological disability. Originally published by Dr. John Rankin in 1957 and subsequently modified by multiple investigators, the mRS has become the primary endpoint in virtually all major stroke clinical trials and is a standard component of stroke outcome assessment in clinical practice worldwide.
The scale consists of seven grades ranging from 0 (no symptoms) to 6 (dead). Grades 0–2 are generally classified as favorable outcomes representing functional independence: Grade 0 indicates no symptoms at all, Grade 1 indicates no significant disability despite symptoms (able to carry out all usual activities and duties), and Grade 2 indicates slight disability (unable to carry out all previous activities but able to look after own affairs without assistance). Grades 3–5 represent increasing levels of dependence: Grade 3 indicates moderate disability (requires some help but able to walk without assistance), Grade 4 indicates moderately severe disability (unable to walk unassisted or attend to bodily needs), and Grade 5 indicates severe disability (bedridden, incontinent, requiring constant nursing care).
The mRS is typically assessed at 90 days post-stroke, which has become the standard timepoint for measuring stroke outcomes. It is used to evaluate the effectiveness of acute treatments (tPA, thrombectomy), rehabilitation programs, and secondary prevention strategies. The scale's simplicity makes it applicable across clinical settings, but standardized training and structured interviews are recommended to improve inter-rater reliability.
This calculator helps clinicians systematically document the mRS score for stroke patients, supporting standardized outcome assessment and communication among providers. It is essential for clinical trial participation, quality metrics reporting, and longitudinal tracking of patient recovery after stroke.
The Modified Rankin Scale assigns a single grade based on the patient's overall level of disability:
In stroke trials, mRS 0–2 is typically classified as a good outcome (functional independence), while mRS 3–6 is classified as a poor outcome.
mRS 0–1 represents excellent outcomes with no significant functional limitation. mRS 2 indicates slight disability but functional independence — patients manage their own daily affairs. mRS 3 indicates moderate disability requiring some assistance but with maintained mobility. mRS 4–5 indicates significant to complete dependence on others for daily activities, with mRS 5 representing the most severe disability compatible with life. mRS 6 represents death.
Inputs
Results
mRS 1 — patient has symptoms but no significant disability. Able to carry out all usual activities.
Inputs
Results
mRS 3 — patient requires some help but able to walk independently. Moderate disability.
The mRS is a 7-point (0–6) ordinal scale measuring the degree of disability or dependence in daily activities following stroke or other neurological conditions, ranging from no symptoms (0) to death (6).
The mRS is most commonly assessed at 90 days (3 months) post-stroke, which is the standard timepoint in stroke clinical trials and outcome studies. It can also be assessed at other timepoints for longitudinal tracking.
mRS 0–2 is generally considered a good or favorable outcome, representing functional independence. Some studies use mRS 0–1 (excellent outcome) or mRS 0–3 (acceptable outcome) as alternative thresholds.
The mRS measures overall disability level on a simple ordinal scale, while the Barthel Index provides a more detailed assessment of specific activities of daily living. The mRS is the preferred primary outcome in stroke trials.
Reliability improves significantly with training and use of structured interviews. Without training, inter-rater agreement is moderate. Standardized mRS training programs and video-based assessment are recommended.
Yes. The mRS can be assessed by telephone or video using structured interview protocols, and these methods have been validated against in-person assessment in stroke clinical trials.
This is the critical threshold of functional independence. mRS 2 patients can manage their own affairs without help, while mRS 3 patients require some assistance. This boundary is the most commonly used dichotomization in stroke trials.
While developed for and most commonly used in stroke, the mRS is also applied to other neurological conditions including traumatic brain injury, subarachnoid hemorrhage, and neurodegenerative diseases.
Post-stroke rehabilitation can significantly improve mRS scores over time. Many patients who initially present with mRS 4–5 improve to mRS 2–3 with appropriate rehabilitation, particularly within the first 3–6 months.
The mRS is a single global measure that may not capture specific deficits, has potential for inter-rater variability without training, and may not be sensitive to small but meaningful changes in function.
Roboculator Team
The Roboculator Team explains calculations, planning tools, and practical formulas in clear language for real-life situations.
How helpful was this calculator?
Be the first to rate!
